血氧水平依赖MRI对同步放化疗宫颈癌患者临床结局的预测价值
研究纳入92例接受同步放化疗的IB2-IVB期宫颈癌患者,治疗前行3-T BOLD MRI测量肿瘤R2*值;有与无疾病进展患者的肿瘤R2*值存在显著差异(p < 0.001),R2*值是PFS(HR = 5.746,p < 0.001)和CSS(HR = 12.878,p = 0.001)的独立因素,读者间信度良好(ICC = 0.702)。
要点
- 治疗前3-T BOLD MRI测量的肿瘤R2*值在有与无疾病进展患者间存在显著差异(p < 0.001)。
- 肿瘤R2*值是PFS(HR = 5.746,p < 0.001)和CSS(HR = 12.878,p = 0.001)的独立因素。
- R2*测量的读者间信度良好(ICC = 0.702)。
核心结论
- 治疗前3-T BOLD MRI可能有助于预测接受同步放化疗的宫颈癌患者的临床结局,且读者间信度良好。
研究设计与样本
- 研究纳入92例接受同步放化疗的IB2-IVB期宫颈癌患者,治疗前行3-T BOLD MRI,测量肿瘤R2*值(s-1),采用Cox回归分析影像与临床参数与PFS和CSS的关联,并以ICC评估R2*测量的读者间信度。
诊断标准与关键数值
- 有与无疾病进展患者的肿瘤R2*值存在显著差异(p < 0.001)。
- 肿瘤R2*值为PFS的独立因素(HR = 5.746,p < 0.001)。
- 肿瘤R2*值为CSS的独立因素(HR = 12.878,p = 0.001)。
- 鳞状细胞癌抗原为PFS的独立因素(HR = 1.027,p = 0.001)。
- R2*测量的读者间信度良好(ICC = 0.702)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the value of blood oxygenation level-dependent (BOLD) MRI as a predictor of clinical outcomes in cervical cancer patients treated with concurrent chemoradiotherapy (CCRT).
METHOD: Enrolled 92 patients with stage IB2-IVB cervical cancer who received CCRT underwent 3-T BOLD MRI before treatment. The R2* value (rate of spin dephasing, s-1) was measured in the tumor. Cox regression analysis was used to evaluate the associations of imaging and clinical parameters with progression-free survival (PFS) and cancer-specific survival (CSS). Inter-reader reliability for the R2* measurements was evaluated using an intraclass correlation coefficient (ICC).
RESULTS: Tumor R2* values were significantly different between patients with and without disease progression (p < 0.001). Multivariate analysis demonstrated that tumor R2* value was significantly independent factor for PFS (hazard ratio [HR] = 5.746, p < 0.001) and CSS (HR = 12.878, p = 0.001). Additionally, squamous cell carcinoma antigen (HR = 1.027, p = 0.001) was significantly independent factor for PFS. Inter-reader reliability for the R2* measurements was good (ICC = 0.702).
CONCLUSION: Pretreatment 3-T BOLD MRI may be useful for predicting clinical outcomes in uterine cervical cancer patients treated with CCRT, with good inter-reader reliability.
KEY POINTS: • Tumor R2* values are different between patients with and without disease progression. • The R2* value is an independent factor for treatment outcomes in cervical cancer. • Inter-reader reliability for R2* measurements using BOLD MRI is good.
引用
- Lee J, Kim CK, Gu KW, et al. Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy. Eur Radiol. 2019. PMID: 31016443. doi:10.1007/s00330-019-06198-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。